Research Synthesis: Deuterium Depleted Water

Abstract

This paper synthesizes deuterium depleted water as an aging-related intervention across 16 included source papers and 493 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct clinical evidence, 10 adjacent clinical sources, and 4 mechanistic or model-system sources, with 51 cross-study disagreements across the evidence base.

No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, mortality and survival and immune and inflammation outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that deuterium depleted water should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-deuterium_depleted_water-v06-DAILY-2026-06-01T07-37-39Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-01.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• deuterium depleted water AND aging
• deuterium-depleted water AND human trial
• deuterium depletion AND mitochondria
• low deuterium water AND cancer AND trial
• DDW AND metabolic health

Eligibility criteria

• Sources whose primary content addresses deuterium depleted water.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 95 records in the receipt-candidate union, 22 were classified as source candidates and 16 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	95
Classified source candidates	22
No extractable claims	26
None-only claim binding	5
Mixed partial-or-none claim-binding candidates	24
Partial-only claim-binding candidates	17
Strict high-confidence sources	1
Admitted final sources	16

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, mortality and survival); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Outcome class	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=10; claims=199	no extracted directional signal in 7/10 sources	5 indirect; 3 mechanistic; 2 review	limited corpus depth in this outcome class
Mortality and Survival	n=4; claims=262	no extracted directional signal in 3/4 sources	3 indirect; 1 mechanistic	limited corpus depth in this outcome class
Cardiometabolic	n=1; claims=8	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Immune and Inflammation	n=1; claims=24	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

10 included sources were assigned to this outcome class. Directional coding: null=7, unclear=3. Directness coding: indirect=5, mechanistic=3, review=2.

Mortality Survival Outcomes

4 included sources were assigned to this outcome class. Directional coding: null=3, unclear=1. Directness coding: indirect=3, mechanistic=1.

Cardiometabolic Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Immune Inflammation Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus lacks any randomized controlled trial of deuterium-depleted water (DDW) and is instead composed entirely of observational cohorts and preclinical models. All clinical evidence derives from uncontrolled designs in which DDW was administered alongside conventional cancer therapy (Somlyai 2025, Somlyai 2023, Boros 2021), making it impossible to isolate the independent contribution of deuterium depletion to the reported survival outcomes. Consequently, the headline conclusion that DDW "multiplies survival probability" rests on evidence that cannot meet conventional efficacy thresholds for causal inference.

Several clinically relevant endpoints are represented by only a single source, precluding internal replication within the corpus. The cardiometabolic outcome class—specifically GLUT4 translocation and insulin-sensitivity markers—is supported by one laboratory study (Kondo 2024) and one preclinical investigation (Molnar 2021), but no human trial has confirmed these glucose-uptake findings in vivo. Immune-inflammation endpoints are likewise touched by a single preclinical source (Rasooli 2019) examining sepsis-induced liver injury in rats, with no corroborating clinical data. Translational relevance to humans remains uncertain. When outcomes depend on lone studies, effect estimates cannot be triangulated and the risk of spurious or context-specific findings remains unquantifiable.

The population base is narrow, restricting external validity. Clinical cohorts enrolled exclusively adult cancer patients—primarily lung, pancreatic, and glioblastoma subtypes (Somlyai 2025, Somlyai 2023, Boros 2021, Gyongyi 2013)—with no evidence in pediatric, pregnant, or elderly non-oncologic populations. Geographic and institutional diversity is also limited; the Hungarian research group behind Somlyai 2025 and Somlyai 2023 accounts for a substantial share of the clinical data, and independent replication outside this network is absent from the corpus. Preclinical animal studies used young-adult rodents (Halenova 2019, Basov 2019), whose metabolic and deuterium-turnover kinetics may not generalize to aged or metabolically compromised humans. The obesity-relevant rat model (Halenova 2019) demonstrated restored body-weight index and serotonin levels after 3 weeks of DDW at 10 ppm, yet no parallel human dietary-intervention trial exists to bridge this finding.

The corpus contains a pronounced mechanism-to-clinic gap: cell-level and animal-model evidence for DDW's anticancer and metabolic mechanisms is relatively rich, but corresponding clinical-effectiveness data are sparse. Similarly, DDW-induced GLUT4 translocation and a reported three- to four-fold increase in glucose uptake under insulin-resistant conditions (Kondo 2024) have not been validated against hard cardiometabolic endpoints such as HbA1c reduction toward the 7% target recommended by ADA 2024. Long-term safety data, dose–response characterization in humans, and quality-of-life outcomes are entirely absent from the curated references. Until controlled trials bridge these mechanistic observations to patient-centered endpoints, the therapeutic promise of deuterium-depleted water remains plausible but unproven.

Conclusion

For deuterium depleted water, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support deuterium depleted water as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 16 included sources on Deuterium depleted water across 4 outcome classes and 51 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 16 curated reference papers, the evidence base for Deuterium depleted water shows a context-dependent profile. Null findings dominate: contextual other, mortality survival. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Deuterium depleted water anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the null vs positive between Somlyai 2023 and Somlyai 2025 on mortality and survival (severity 3/5), which defines the boundary condition future studies must test rather than smooth over.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Outcome class	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	0	1	null	direct clinical gap
contextual adjacent evidence	0	10	null, unclear	direct clinical gap
mortality and survival	0	4	null, unclear	direct clinical gap
immune and inflammation	0	1	null	direct clinical gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P2	contextual adjacent evidence: direct clinical gap	0 direct and 10 indirect sources; direction profile: null, unclear
P3	mortality and survival: direct clinical gap	0 direct and 4 indirect sources; direction profile: null, unclear
P4	immune and inflammation: direct clinical gap	0 direct and 1 indirect source; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Deuterium depleted water should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

Additional corpus sources included animal/preclinical evidence; - Somlyai 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=mortality survival; direction=unclear; representative statistic=P < 0.001.

• Somlyai 2023; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=mortality survival; direction=null.
• Boros 2021; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=mortality survival; direction=null; representative statistic=P < 0.001.
• Korchinsky 2024; Observational; tier=B2; directness=review; N=—; population=—; endpoint=contextual other; direction=null; representative statistic=P = 0.0019.
• Rasooli 2019; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=P < 0.05.
• Molnar 2021; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.001.
• Zhang 2019; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.005.
• Lu 2024; Observational; tier=B2; directness=review; N=—; population=—; endpoint=contextual other; direction=unclear.
• Basov 2019b; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null.
• Kondo 2024; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=cardiometabolic; direction=null; representative statistic=P < 0.05.

Load-Bearing Tensions

Additional corpus sources included animal/preclinical evidence; - Severity 3 null vs positive: Somlyai 2023 vs Somlyai 2025; Somlyai 2023 (null) vs Somlyai 2025 (unclear) on mortality survival

• Severity 3 null vs positive: Lu 2024 vs Yaglova 2024; Lu 2024 (unclear) vs Yaglova 2024 (null) on contextual other
• Severity 3 null vs positive: Lu 2024 vs Korchinsky 2024; Lu 2024 (unclear) vs Korchinsky 2024 (null) on contextual other
• Severity 3 null vs positive: Lu 2024 vs Li 2025; Lu 2024 (unclear) vs Li 2025 (null) on contextual other
• Severity 3 null vs positive: Lu 2024 vs Goncharuk 2013; Lu 2024 (unclear) vs Goncharuk 2013 (null) on contextual other
• Severity 3 null vs positive: Lu 2024 vs Basov 2019b; Lu 2024 (unclear) vs Basov 2019b (null) on contextual other
• Severity 3 null vs positive: Lu 2024 vs Zhang 2019; Lu 2024 (unclear) vs Zhang 2019 (null) on contextual other
• Severity 3 null vs positive: Lu 2024 vs Molnar 2021; Lu 2024 (unclear) vs Molnar 2021 (null) on contextual other

References

• Somlyai 2025. Real-World Data Confirm That the Integration of Deuterium Depletion into Conventional Cancer Therapy Multiplies the Survival Probability of Patients. Biomedicines, 2025. DOI: 10.3390/biomedicines13040876. PMID: 40299476.
• Somlyai 2023. A Preliminary Study Indicating Improvement in the Median Survival Time of Glioblastoma Multiforme Patients by the Application of Deuterium Depletion in Combination with Conventional Therapy. Biomedicines, 2023. DOI: 10.3390/biomedicines11071989. PMID: 37509628.
• Boros 2021. Deuterium Depletion Inhibits Cell Proliferation, RNA and Nuclear Membrane Turnover to Enhance Survival in Pancreatic Cancer. Cancer Control : Journal of the Moffitt Cancer Center, 2021. DOI: 10.1177/1073274821999655. PMID: 33760674.
• Halenova 2019. Deuterium-Depleted Water as Adjuvant Therapeutic Agent for Treatment of Diet-Induced Obesity in Rats. Molecules, 2019. DOI: 10.3390/molecules25010023. PMID: 31861678.
• Basov 2019. Influence of Deuterium-Depleted Water on the Isotope D/H Composition of Liver Tissue and Morphological Development of Rats at Different Periods of Ontogenesis. Iranian Biomedical Journal, 2019. DOI: 10.29252/.23.2.129. PMID: 30220191.
• Korchinsky 2024. Nutritional deuterium depletion and health: a scoping review. Metabolomics, 2024. DOI: 10.1007/s11306-024-02173-4. PMID: 39397213.
• Rasooli 2019. Synergistic effects of deuterium depleted water and Mentha longifolia L. essential oils on sepsis-induced liver injuries through regulation of cyclooxygenase-2. Pharmaceutical Biology, 2019. DOI: 10.1080/13880209.2018.1563622. PMID: 30961427.
• Molnar 2021. Deuterium-depleted water stimulates GLUT4 translocation in the presence of insulin, which leads to decreased blood glucose concentration. Molecular and Cellular Biochemistry, 2021. DOI: 10.1007/s11010-021-04231-0. PMID: 34510301.
• Zhang 2019. Anticancer Effect of Deuterium Depleted Water - Redox Disbalance Leads to Oxidative Stress *. Molecular & Cellular Proteomics : MCP, 2019. DOI: 10.1074/mcp.RA119.001455. PMID: 31519768.
• Yaglova 2024. Effects of Deuterium Depletion on Age-Declining Thymopoiesis In Vivo. Biomedicines, 2024. DOI: 10.3390/biomedicines12050956. PMID: 38790918.
• Lu 2024. Deuterium-Depleted Water in Cancer Therapy: A Systematic Review of Clinical and Experimental Trials. Nutrients, 2024. DOI: 10.3390/nu16091397. PMID: 38732643.
• Basov 2019b. Deuterium-Depleted Water Influence on the Isotope 2 H/ 1 H Regulation in Body and Individual Adaptation. Nutrients, 2019. DOI: 10.3390/nu11081903. PMID: 31443167.
• Kondo 2024. Study of the Effects of Deuterium-Depleted Water on the Expression of GLUT4 and Insulin Resistance in the Muscle Cell Line C2C12. Biomedicines, 2024. DOI: 10.3390/biomedicines12081771. PMID: 39200235.
• Gyongyi 2013. Deuterium Depleted Water Effects on Survival of Lung Cancer Patients and Expression of Kras, Bcl2, and Myc Genes in Mouse Lung. Nutrition and Cancer, 2013. DOI: 10.1080/01635581.2013.756533. PMID: 23441611.
• Goncharuk 2013. Revealing water’s secrets: deuterium depleted water. Chemistry Central Journal, 2013. DOI: 10.1186/1752-153X-7-103. PMID: 23773696.
• Li 2025. Deuterium-depleted water inhibits the malignant progression of colorectal cancer cells by modulating oxidative stress. Oncology Reports, 2025. DOI: 10.3892/or.2025.8903. PMID: 40314087.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.